Departure Of Alexander Hardy & Appointment of Ashley Magargee as Interim Chief Executive Officer Genentech

Alexander Hardy, Chief Executive Officer of Genentech, a member of the Roche Group, has decided to leave the company and will step down from his role on November 1st 2023. Hardy first joined Genentech in 2005 and held several senior management positions before assuming the role of CEO in March 2019. Ashley Magargee, Head of US Commercial Portfolio, who has been serving as ad interim CEO during Alexander's recent sabbatical, will continue in this role until a successor is announced. Magargee joined Genentech in 2004 and previously held senior management positions at Roche and Genentech in lifecycle management, digital customer experience, market access and was also General Manager in Singapore.

About Genentech

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit